Bellerophon Therapeutics

February 1, 2019February 7, 2019

Actigraphy is Clinically Meaningful Tool in PH-IPF Patients Treated with iNOpulse

News

Results of a Phase 2b clinical trial suggest actigraphy as a relevant tool to detect meaningful clinical changes in patients with pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) ... Read more

January 10, 2018January 10, 2018

First Patient Enrolls in Phase 2b Trial of INOpulse Nitric Oxide Delivery System

News

Bellerophon Therapeutics has enrolled the first pulmonary hypertension patient in a Phase 2b clinical trial of its INOpulse nitric oxide delivery system. The trial (NCT03267108) of the blood-vessel-widening device will ... Read more

June 22, 2016June 22, 2016

Bellerophon Enrolls 1st PAH Patient in Phase 3 Study of INOpulse Device

News

Bellerophon Therapeutics recently announced that the Phase 3 INOvation-1 clinical trial evaluating the safety and efficacy of the INOpulse delivery of nitric oxide (NO) in patients with pulmonary arterial hypertension ... Read more

Pin It on Pinterest